Clinical Report: EASO Pharmacological Algorithm for Obesity Management
Overview
The European Association for the Study of Obesity (EASO) has introduced a grade-based pharmacological algorithm that integrates recent advances in obesity medications with a complication-focused staging system. This framework supports evidence-based, personalized treatment of obesity and its related complications, moving beyond BMI-centric approaches.
Background
Obesity is now recognized as a chronic, adipose-based disease with two main categories: fat mass disease and sick fat disease, each linked to distinct complications. Traditional management focused on lifestyle and surgery often yielded limited long-term success. The emergence of next-generation obesity management medications (OMMs), such as GLP-1 receptor agonists and dual GIP/GLP-1 agonists, has transformed treatment by achieving substantial weight loss and improving obesity-related complications. The EASO framework provides a structured, evidence-based approach to guide pharmacological treatment in this evolving landscape.
Data Highlights
Recent clinical trials demonstrate that OMMs can induce total body weight loss of 15%-22%, comparable to bariatric surgery outcomes. The network meta-analysis informing the EASO framework included subgroup analyses by BMI and showed consistent efficacy across various endpoints. Safety profiles of most OMMs were favorable, supporting their long-term use. However, data gaps remain regarding long-term durability, under-represented populations, and head-to-head comparisons.
Key Findings
Obesity is classified into fat mass disease (mechanical complications) and sick fat disease (metabolic/cardiovascular complications), necessitating tailored treatment strategies.
The EASO pharmacological algorithm grades OMMs based on scientific evidence and clinical priorities, integrating obesity-related complications beyond BMI.
Next-generation OMMs achieve 15%-22% weight loss and improve complications such as obstructive sleep apnea, type 2 diabetes, heart failure, and liver disease.
The framework emphasizes treating both fat mass accumulation and organ dysfunction, promoting a person-centered approach.
Limitations include limited long-term data, under-representation of certain populations, lack of head-to-head trials, and disparities in drug access.
Clinicians should adopt the EASO grade-based algorithm to guide pharmacological obesity treatment tailored to individual complication profiles rather than relying solely on BMI. The demonstrated efficacy and safety of next-generation OMMs support their long-term use in appropriate patients. However, ongoing monitoring and integration of lifestyle interventions remain critical for sustained health benefits.
Conclusion
The EASO pharmacological algorithm marks a pivotal advancement in structured, evidence-driven obesity management by aligning treatment with complication-based staging. Continued refinement and broader implementation will enhance personalized, patient-centered care in obesity.
References
EASO Working Group 2024 -- A Clinical Perspective on the Pharmacological Algorithm for Obesity Management Based on EASO Grading
